Evolving indications and long-term oncological outcomes of risk-reducing bilateral nipple-sparing mastectomy.
Adult
Aged
Biomarkers, Tumor
/ genetics
Breast Neoplasms
/ genetics
Breast Neoplasms, Male
/ genetics
Female
Follow-Up Studies
Germ-Line Mutation
Humans
Male
Mastectomy, Subcutaneous
/ adverse effects
Medical History Taking
Middle Aged
Nipples
/ surgery
Organ Sparing Treatments
/ adverse effects
Patient Selection
Prophylactic Mastectomy
/ adverse effects
Retrospective Studies
Treatment Outcome
Young Adult
Journal
BJS open
ISSN: 2474-9842
Titre abrégé: BJS Open
Pays: England
ID NLM: 101722685
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
08
07
2018
accepted:
25
09
2018
entrez:
9
4
2019
pubmed:
9
4
2019
medline:
9
4
2019
Statut:
epublish
Résumé
Bilateral nipple-sparing mastectomy (NSM) is a technically feasible operation and is associated with excellent cosmetic outcomes. The aim of this study was to evaluate trends in patient characteristics, indications for surgery and long-term outcomes of bilateral NSM for breast cancer risk reduction over time. A review of a single-centre experience with bilateral NSM performed between 2001 and 2017 for breast cancer risk reduction in patients without breast cancer was performed. Trends in patient characteristics and indications for surgery were evaluated over four time intervals: 2001-2005, 2006-2009, 2010-2013 and 2014-2017. Statistical analysis was performed using χ Over the study period, 272 NSMs were performed in 136 patients; their median age was 41 years. The number of bilateral NSMs performed increased over time. The most common indication was a mutation in breast cancer-associated genes (104 patients, 76·5 per cent), which included The use of bilateral NSM for breast cancer risk reduction is increasing and the indications have evolved over the past 16 years. These excellent long-term oncological results suggest that bilateral NSM is a good option for surgical breast cancer risk reduction.
Sections du résumé
Background
Bilateral nipple-sparing mastectomy (NSM) is a technically feasible operation and is associated with excellent cosmetic outcomes. The aim of this study was to evaluate trends in patient characteristics, indications for surgery and long-term outcomes of bilateral NSM for breast cancer risk reduction over time.
Methods
A review of a single-centre experience with bilateral NSM performed between 2001 and 2017 for breast cancer risk reduction in patients without breast cancer was performed. Trends in patient characteristics and indications for surgery were evaluated over four time intervals: 2001-2005, 2006-2009, 2010-2013 and 2014-2017. Statistical analysis was performed using χ
Results
Over the study period, 272 NSMs were performed in 136 patients; their median age was 41 years. The number of bilateral NSMs performed increased over time. The most common indication was a mutation in breast cancer-associated genes (104 patients, 76·5 per cent), which included
Conclusion
The use of bilateral NSM for breast cancer risk reduction is increasing and the indications have evolved over the past 16 years. These excellent long-term oncological results suggest that bilateral NSM is a good option for surgical breast cancer risk reduction.
Identifiants
pubmed: 30957063
doi: 10.1002/bjs5.50117
pii: BJS550117
pmc: PMC6433310
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Pagination
169-173Références
N Engl J Med. 1999 Jan 14;340(2):77-84
pubmed: 9887158
Clin Breast Cancer. 2017 Jul;17(4):e209-e213
pubmed: 28162950
Breast Cancer. 2016 Nov;23(6):851-860
pubmed: 26464007
Clin Cancer Res. 2012 Jan 15;18(2):400-7
pubmed: 22252256
Ann Surg Oncol. 2015 Feb;22(2):370-6
pubmed: 25023546
J Am Coll Surg. 2006 Nov;203(5):704-14
pubmed: 17084333
J Clin Oncol. 2014 Jul 20;32(21):2217-23
pubmed: 24752044
Arch Surg. 2004 Feb;139(2):148-50
pubmed: 14769571
J Breast Cancer. 2016 Jun;19(2):218-21
pubmed: 27382401
Gland Surg. 2015 Dec;4(6):467-75
pubmed: 26645001
Aesthetic Plast Surg. 1989 Winter;13(1):15-21
pubmed: 2728994
J Am Coll Surg. 2018 Apr;226(4):560-565
pubmed: 29360614
Nat Rev Clin Oncol. 2016 Sep;13(9):581-8
pubmed: 27296296
Breast. 2016 Feb;25:75-81
pubmed: 26612083
J Am Coll Surg. 2011 Apr;212(4):686-93; discussion 693-5
pubmed: 21463813
Am J Surg Pathol. 2014 May;38(5):706-12
pubmed: 24698963
Ann Surg Oncol. 2016 Oct;23(10):3221-5
pubmed: 27380643
Ann Surg Oncol. 2018 Oct;25(10):2909-2916
pubmed: 29968023
Ann Surg Oncol. 2011 Oct;18(11):3102-9
pubmed: 21947588
Br J Surg. 2015 Oct;102(11):1354-9
pubmed: 26313374
N Engl J Med. 2015 Jun 4;372(23):2243-57
pubmed: 26014596
JAMA Surg. 2018 Feb 1;153(2):123-129
pubmed: 28903167
N Engl J Med. 2001 Jul 19;345(3):159-64
pubmed: 11463009
Plast Reconstr Surg. 2010 Mar;125(3):818-29
pubmed: 20195110
Arch Surg. 2008 Nov;143(11):1106-10; discussion 1110
pubmed: 19015470
Breast J. 2016 Jan-Feb;22(1):10-7
pubmed: 26782950
Gland Surg. 2016 Jun;5(3):306-11
pubmed: 27294038
Ann Chir Plast Esthet. 2018 Jun;63(3):e6-e13
pubmed: 29030030
Ann Surg Oncol. 2011 Jun;18(6):1665-70
pubmed: 21174155
Ann Surg Oncol. 2014 Jan;21(1):37-41
pubmed: 23982256